When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Despite our most vigorous efforts, prostate cancer remains the second leading cause of cancer death in men. Understanding the intricacies of androgen metabolism is vital to finding therapeutic ...

Here we show that suppression of caveolin expression by a stably transfected antisense caveolin-1 cDNA vector converted androgen-insensitive metastatic mouse prostate cancer cells to an androgen ...

A mid-stage study reveals that transdermal estradiol patches may match traditional androgen deprivation therapy in treating prostate cancer with fewer side effects. This approach boosts bone density ...

Hormonal therapy, namely targeting androgen signaling, has continued to be the mainstay of treatment for advanced prostate cancer, going all the way back to the 1940s when we first started using ...

Prostate cancer hijacks the normal ... causing the expression of some genes and suppression of others. But in cancer, the androgen receptor is reprogrammed to tell the cells to continue growing ...

Dr. Elahe Mostaghel studies how prostate cancer becomes resistant to therapies that deprive tumors of androgen hormones, such as testosterone, and she is developing new drugs to target them. Androgens ...

Explore the role of the extracellular matrix (ECM) in prostate cancer progression and discover natural therapies, including milk thistle, turmeric, and green tea, that target the tumor ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.